semaglutide and cardiac risk Cardiovascular Outcomes in Obesity without Diabetes A big win for Wegovy:

[4] [5] This shift in fat distribution carries particular health implications, as visceral adiposity is associated with increased cardiovascular risk, type 2 diabetes, and metabolic syndrome

If youre pregnant, breastfeeding, severely immunocompromised, or have a central line, avoid live probiotics unless your clinician approves

DPPD, N,N -diphenyl-p-phenylene diamine

Meta-analyses pooling trial data indicated statistically significant differences favoring tirzepatide for percent weight loss, but semaglutide remained highly effective and better tolerated by some participants, notably in community practice

CRISPR-Cas-9 is a revolutionary therapeutic intervention

[40] demonstrated increased iron accumulation, decreased GPX4 expression and marked neuronal damage that were prevented by ferrostatin-1